on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Position on Avadel Pharmaceuticals plc
The Vanguard Group, Inc. has filed a Form 8.3 with the Irish Takeover Panel regarding its interests in Avadel Pharmaceuticals plc. This disclosure is necessary under Rule 8.3 of the Irish Takeover Rules, given Vanguard's significant holdings. As of February 9, 2026, Vanguard holds 5,672,705 ordinary shares in Avadel, representing a 5.82% stake.
Recent transactions include the purchase of 524 shares and the sale of 125,590 shares at approximately 21.62-21.65 USD per share. Vanguard's filing indicates no current indemnity or option arrangements related to these transactions. This transparency aligns with regulatory requirements for entities possessing 1% or more of relevant securities in the context of a potential takeover scenario.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news